A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS in Prostate Cancer Prevention
Latest Information Update: 17 Jun 2024
At a glance
- Drugs MCS 8 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Health Ever Bio-Tech
Most Recent Events
- 11 Jun 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 26 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 11 May 2021 Planned primary completion date changed from 1 Mar 2023 to 1 Dec 2023.